SEC Tracker
Get the app

Xilio Therapeutics XLO

Xilio Therapeutics announces Q3 2026 financial results

Xilio Therapeutics (XLO) filed an 8-K with the SEC on Nov 10, 2026, 7:35 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Dosed first patient in Phase 1/2 trial for XTX501 in metastatic NSCLC
  2. Planned IND submissions for XTX602 and XTX701 in Q4 2027
  3. Efarindodekin alfa Phase 2 trial ongoing with Gilead data update expected in H1 2027

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Xilio Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.